However, in terms of different pathological subtypes, no significant difference in DFS or OS rates was observed in HR+HER2- IBC patients based on high or low PIV values (Figure 4A), but HER2+ and TNBC IBC patients in high PIV group had statistically significantly worse survival rates (Figures 4B,C). The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.